Taris Completes Phase 1 Study

Taris Biomedical (Taris) has reported the completion of Phase 1 clinical study of its intravesical drug-device convergence system designed to provide sustained-release of drug directly to the bladder.

The study was designed to evaluate the safety, tolerability and retention of the Taris drug-device convergence system in the bladder. The detailed results have been embargoed pending scientific publication.

The company said that the Taris core platform technology, which was developed by MIT, enables local sustained delivery of drug directly to the target tissue through drug-device convergence.

Christine Bunt, co-founder and COO of Taris, said: “In just one year we have rapidly advanced this technology from in-licensing through Phase 1 human clinical testing.

“This Phase 1 study successfully establishes proof-of-concept for the Taris sustained-release technology and positions us for mid-stage clinical development with our LiRIS (Lidocaine Releasing Intravesical System) in interstitial cystitis (IC), our first indication, in 2010.”